Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Pictured: A scientist works behind an FDA sign/Tay

FDA Tracker

2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval

Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.

December 24, 2024

223 min read

BioSpace Editorial Staff

Eli Lilly's biotechnology center in California

GLP-1

Lilly’s Zepbound Snags First Ever Sleep Apnea Drug Approval

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

December 23, 2024

2 min read

Kate Goodwin

Multi-directional arrows on yellow background , choose between several potential future options and scenarios,3d rendering

GLP-1

7 Indications for GLP-1s Beyond Weight Loss

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists also show potential in several other indications, including cancer, addiction and neurodegenerative diseases.

December 23, 2024

11 min read

Tristan Manalac

Young businessman jumping through gap cliff at sunrise time with modern city background

GLP-1

Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.

December 20, 2024

3 min read

Annalee Armstrong

Drug shortages

FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period

After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s.

December 19, 2024

3 min read

Tristan Manalac

Sketch of people teamwork, gears, production. Doodle cartoon mechanism with machinery and cogwheels. Hand drawn vector illustration for business and industry design isolated on white.

Manufacturing

Biopharma’s Big Question of 2024: Can You Scale It?

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

December 18, 2024

5 min read

Annalee Armstrong

Podcast

Biopharma’s Manufacturing Push and Other 2024 Trends

The Novo-Catalent deal now moving ahead highlights unprecedented investment in manufacturing, while also standing out as an exception to the unspoken rule of keeping M&As to less than $5 billion this year.

December 18, 2024

1 min read

Jef Akst

Government

Lilly, Pfizer Execs Sing Optimistic Tune on Incoming Admin After Trump Dinner

A week after dining with Trump and his team at Mar-a-Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration on key issues affecting the pharma industry.

December 12, 2024

2 min read

Tristan Manalac

Сontemporary art collage of human hands holding french fries or chips. Modern design. Copy space for ad.

Mergers & Acquisitions

Pharma Has Kept M&A Spending Small This Year, With Just One Deal Topping $5B

By far, the largest acquisition of 2024 was Novo Holdings’ yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.

December 11, 2024

4 min read

Annalee Armstrong

JOBS